🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: SGLT2 inhibitor, GLP-1 RA

Found 15 matching trials

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

In traditional step-up approach, the patients with poorly-controlled type 2...

Status

Completed

Location

UCSF Fresno

Start Date

2016-08

Trial ID

NCT02846233

Treatments Being Tested

GLP1 receptor agonist basal insulin SGLT2 inhibitor Metformin

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

N/A

To perform an observational analysis to emulate a target trial (i.e., a hyp...

Status

Active Not Recruiting

Location

Brigham and Women's Hospital

Start Date

2021-08-01

Trial ID

NCT05220917

Treatments Being Tested

SGLT2 inhibitor DPP-4 inhibitor GLP-1RA 2nd generation SU

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

PHASE3

Primary Objective: To demonstrate the superiority of the insulin glargine/...

Status

Completed

Location

Investigational Site Number 8400064

Start Date

2016-07-06

Trial ID

NCT02787551

Treatments Being Tested

Insulin glargine/lixisenatide fixed ratio combination liraglutide exenatide exenatide extended-release albiglutide dulaglutide Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)

Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease

N/A

This retrospective observational target-trial emulation uses electronic hea...

Status

Completed

Location

Multiple Locations

Start Date

2017-01-01

Trial ID

NCT07566299

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

PHASE4

The use of semaglutide in patients with DMT2 and psoriasis contributes to i...

Status

Completed

Location

University of Banja Luka, Faculty of Medicine

Start Date

2023-05-03

Trial ID

NCT06475586

Treatments Being Tested

Semaglutide

Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

N/A

This retrospective observational target-trial emulation uses electronic hea...

Status

Completed

Location

Multiple Locations

Start Date

2017-01-01

Trial ID

NCT07465926

Treatments Being Tested

GLP-1 receptor agonist SGLT2 inhibitor

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

Diabetes is a disorder of high blood glucose, that tends to get worse; over...

Status

Active Not Recruiting

Location

Atlanta VA Medical Center

Start Date

2021-09-01

Trial ID

NCT05040087

Treatments Being Tested

Intensification of diabetes medication based largely on HbA1c levels Intensification of diabetes medication based on glucose levels

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

N/A

This is an observational study in which data from people with chronic kidne...

Status

Completed

Location

Optum CDM

Start Date

2022-10-01

Trial ID

NCT05526157

Treatments Being Tested

Finerenone (Kerendia, BAY 948862)Sodium-glucose cotransporter 2 inhibitors (SGLT2i)Glucagon-like peptide-1 receptor agonists (GLP 1 RA)Steroidal mineral corticoid receptor antagonists (sMRA)Non-steroidal mineral corticoid receptor antagonists (nsMRA)

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

PHASE4

Minorities have higher rates of diabetes, poorer glucose control, and highe...

Status

Active Not Recruiting

Location

SUNY Downstate Health Sciences University

Start Date

2024-12-21

Trial ID

NCT07325435

Treatments Being Tested

SGLT-2 inhibitor GLP1-RA

Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes

N/A

This retrospective observational target-trial emulation uses electronic hea...

Status

Not Yet Recruiting

Location

Chung Shan Medical University Hospital

Start Date

2026-07-31

Trial ID

NCT07708610

Previous Next